This Aussie pot stock is up 460% since May

The Cann Group Ltd (ASX:CAN) share price has surged higher again today and is now up 460% since hitting the ASX boards in May…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It is quickly becoming a case of another day, another all-time high for the Cann Group Ltd (ASX: CAN) share price.

The medicinal cannabis company's shares have continued their stellar run and climbed 7% to an all-time of $1.68 in morning trade.

Incredibly, this means that Cann's shares have now risen a remarkable 460% since hitting the ASX boards at 30 cents per share in May.

Why are its shares higher today?

This morning Cann announced that the Office of Drug Control has granted it a licence to import and export cannabis genetics and medicinal cannabis.

According to the release, this means the company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing.

The licence also allows it to apply for a permit to import cannabis genetics and medicinal cannabis products from legal international sources.

Management believes the licence is an important milestone in its goal of building a genetic database of locally and internationally sourced cannabis strains for cultivation under its medicinal cannabis licence.

Furthermore, it is seen as a key step in its plan to import medicinal cannabis products for supply to Australian patients and will complement the locally manufactured products that use cannabis cultivated by Cann.

Should you invest?

Along with Auscann Group Holdings Ltd (ASX: AC8), I think Cann is one of the best positioned medicinal cannabis companies in Australia.

However, I feel there is still a lot of work ahead before either of these companies are generating meaningful revenues. Because of this, I continue to believe that investors ought to keep them on their watchlists and wait for sales data that supports their lofty market valuations.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »